Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907969 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03907969 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants.
The verdict
NCT03907969, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or novel anti-cancer agents in participants with advanced malignancies.
Interventions
- DRUG PLD
- DRUG AZD7648
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-10-09 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03907969
The ClinicalTrials.gov registry entry for NCT03907969 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PLD is the first listed.
NCT03907969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03907969 about?
NCT03907969 is a clinical study titled "A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.". This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or novel anti-cancer agents in participants with advanced malignancies.
What is the current status of trial NCT03907969?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-10-09. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT03907969?
The interventions under investigation include: PLD (DRUG), AZD7648 (DRUG).
Who is sponsoring clinical trial NCT03907969?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.